• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性肥大性骨关节病患者使用非甾体抗炎药的疗效:系统评价。

Effectiveness of non-steroidal anti-inflammatory drugs among patients with primary hypertrophic osteoarthropathy: A systematic review.

机构信息

Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Japan.

Health Research and Social Development Forum (HERD), P.O. Box 24133, Thapathali, Kathmandu, Nepal.

出版信息

J Dermatol Sci. 2018 Apr;90(1):21-26. doi: 10.1016/j.jdermsci.2017.12.012. Epub 2017 Dec 28.

DOI:10.1016/j.jdermsci.2017.12.012
PMID:29305259
Abstract

BACKGROUND

Primary hypertrophic osteoarthropathy (PHO), also known as pachydermoperiostosis is a rare genetic disease which predominantly affects skin, bone and soft connective tissue. It is characterized by the triad of pachydermia, digital clubbing and periostosis of long bones. Arthralgia or arthritis is also present in most of the cases. Genetic studies have identified the impaired PGE2 metabolism as a culprit for hypertrophic osteoarthropathy in PHO cases. We conducted a systematic review to examine the effectiveness of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a PGE2 synthesis blocker to reduce the symptoms among PHO patients.

METHODS

We searched the evidence in five databases; Cochrane Library, CINAHL, EMBASE, MEDLINE, and PubMed. We reported the evidence using narrative synthesis.

RESULTS

Out of 238 identified studies, we selected 26 for the synthesis. All were case reports which included a total of 54 patients. Among them, 39 patients were treated with at least one type of NSAIDs. Around 70% of the patients treated with NSAIDs had clinical improvement for their symptoms, mostly arthritis or arthralgia symptoms.

CONCLUSION

NSAIDs were effective in improving arthralgia or arthritis symptoms in majority of the PHO patients. Therefore, we recommend the use of NSAIDs in PHO patients to treat arthralgia or arthritis.

摘要

背景

原发性肥大性骨关节病(PHO),又称厚皮性骨膜病,是一种罕见的遗传性疾病,主要影响皮肤、骨骼和软结缔组织。其特征为三联征,即皮肤增厚、杵状指(趾)和长骨骨膜增生。大多数病例还存在关节痛或关节炎。遗传研究表明,前列腺素 E2(PGE2)代谢受损是 PHO 患者发生肥大性骨关节病的罪魁祸首。我们进行了一项系统评价,以检查非甾体抗炎药(NSAIDs),即 PGE2 合成抑制剂,对减轻 PHO 患者症状的有效性。

方法

我们在五个数据库中搜索证据,即 Cochrane Library、CINAHL、EMBASE、MEDLINE 和 PubMed。我们使用叙述性综合报告证据。

结果

在 238 项已确定的研究中,我们选择了 26 项进行综合分析。这些研究均为病例报告,共纳入了 54 名患者。其中,39 名患者接受了至少一种 NSAIDs 的治疗。接受 NSAIDs 治疗的患者中,约 70%的患者症状得到了临床改善,主要是关节炎或关节痛症状。

结论

NSAIDs 对大多数 PHO 患者的关节痛或关节炎症状有效。因此,我们建议在 PHO 患者中使用 NSAIDs 来治疗关节痛或关节炎。

相似文献

1
Effectiveness of non-steroidal anti-inflammatory drugs among patients with primary hypertrophic osteoarthropathy: A systematic review.原发性肥大性骨关节病患者使用非甾体抗炎药的疗效:系统评价。
J Dermatol Sci. 2018 Apr;90(1):21-26. doi: 10.1016/j.jdermsci.2017.12.012. Epub 2017 Dec 28.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块型银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5.
3
Rofecoxib for rheumatoid arthritis.用于类风湿性关节炎的罗非昔布
Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD003685. doi: 10.1002/14651858.CD003685.pub2.
4
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
5
WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee.撤回:用于治疗膝关节骨关节炎的非阿司匹林非甾体抗炎药。
Cochrane Database Syst Rev. 2007 Jul 18;2006(1):CD000142. doi: 10.1002/14651858.CD000142.pub2.
6
Non-steroidal anti-inflammatory agents for treating cystoid macular edema following cataract surgery.非甾体类抗炎药治疗白内障术后囊样黄斑水肿。
Cochrane Database Syst Rev. 2022 Dec 15;12(12):CD004239. doi: 10.1002/14651858.CD004239.pub4.
7
Non-steroidal anti-inflammatory drugs for acute gout.非甾体抗炎药治疗急性痛风。
Cochrane Database Syst Rev. 2021 Dec 9;12(12):CD010120. doi: 10.1002/14651858.CD010120.pub3.
8
Interventions for central serous chorioretinopathy: a network meta-analysis.中心性浆液性脉络膜视网膜病变的干预措施:一项网状Meta分析
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
9
Laser therapy for treating hypertrophic and keloid scars.激光疗法治疗增生性瘢痕和瘢痕疙瘩。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD011642. doi: 10.1002/14651858.CD011642.pub2.
10
Survivor, family and professional experiences of psychosocial interventions for sexual abuse and violence: a qualitative evidence synthesis.性虐待和暴力的心理社会干预的幸存者、家庭和专业人员的经验:定性证据综合。
Cochrane Database Syst Rev. 2022 Oct 4;10(10):CD013648. doi: 10.1002/14651858.CD013648.pub2.

引用本文的文献

1
A Loss-of-Function Variant Causing Primary Autosomal Recessive Hypertrophic Osteoarthropathy.一种导致原发性常染色体隐性肥大性骨关节病的功能丧失变异体。
Cureus. 2025 Jul 19;17(7):e88312. doi: 10.7759/cureus.88312. eCollection 2025 Jul.
2
Two cases of primary hypertrophic osteoarthropathy caused by HPGD variants: a case report and literature review.两例由HPGD基因变异引起的原发性肥厚性骨关节病:病例报告及文献综述
BMC Pediatr. 2025 Mar 27;25(1):238. doi: 10.1186/s12887-025-05590-z.
3
Pachydermoperiostosis Due to a Novel Splicing Site Mutation Masquerading as Acromegaly.
因一种伪装成肢端肥大症的新型剪接位点突变导致的厚皮性骨膜病。
JCEM Case Rep. 2024 Dec 3;2(12):luae215. doi: 10.1210/jcemcr/luae215. eCollection 2024 Dec.
4
Role of bisphosphonates in hypertrophic osteoarthropathy: a systematic review.双膦酸盐在肥大性骨关节病中的作用:系统评价。
Endocrine. 2024 Aug;85(2):883-893. doi: 10.1007/s12020-024-03804-5. Epub 2024 Apr 2.
5
Pachydermoperiostosis: a case report of initial improvement with etoricoxib.厚皮性骨膜病:依托考昔初始治疗有效的病例报告
Ann Med Surg (Lond). 2023 Aug 14;85(10):5153-5157. doi: 10.1097/MS9.0000000000001146. eCollection 2023 Oct.
6
Primary hypertrophic osteoarthropathy: genetics, clinical features and management.原发性肥大性骨关节病:遗传学、临床特征与治疗。
Front Endocrinol (Lausanne). 2023 Aug 29;14:1235040. doi: 10.3389/fendo.2023.1235040. eCollection 2023.
7
Complete form of pachydermoperiostosis with good initial response to etoricoxib: A case report.对依托考昔初始反应良好的厚皮性骨膜病完全型:一例报告
Clin Case Rep. 2023 Jun 13;11(6):e7526. doi: 10.1002/ccr3.7526. eCollection 2023 Jun.
8
A patient with pachydermoperiostosis harboring variants with a history of differentiating from acromegaly.一名患有厚皮性骨膜病的患者,携带与肢端肥大症相鉴别的变异史。
Bone Rep. 2023 Mar 16;18:101673. doi: 10.1016/j.bonr.2023.101673. eCollection 2023 Jun.
9
Primary hypertrophic osteoarthropathy - a rare cause of pain and arthritis in children. Description of 5 cases.原发性肥大性骨关节病——儿童疼痛和关节炎的罕见病因。5例病例描述。
Cent Eur J Immunol. 2022;47(3):280-287. doi: 10.5114/ceji.2022.120171. Epub 2022 Nov 16.
10
Etoricoxib as a treatment of choice for patients with mutation exhibiting autosomal recessive primary hypertrophic osteoarthropathy: A case report.依托考昔作为治疗表现为常染色体隐性原发性肥厚性骨关节病突变患者的首选药物:一例病例报告。
Front Genet. 2022 Dec 13;13:1053999. doi: 10.3389/fgene.2022.1053999. eCollection 2022.